Targeted and Immune Therapies in Non-small Cell Lung Cancer—Latest Advances
Keyword(s):
In recent years the treatment landscape of non-small cell lung cancer (NSCLC) has been transformed. The emergence of therapies targeting specific genetic alterations, such as epidermal growth factor (EGFR) mutations, as well as immune checkpoint inhibitors targeting the transmembrane protein programmed death-1 (PD1) and its ligand (PDL1), has increased the therapeutic options for patients with NSCLC. In an expert interview, Suresh S Ramalingam discusses recent advances in targeted and immune therapy and considers the role of chemotherapy within this rapidly evolving therapeutic paradigm.
2016 ◽
Vol 21
(4)
◽
pp. 179-185
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2020 ◽
Vol 16
(1)
◽
pp. 5-10
Keyword(s):